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Abstract 
Inhaled antibiotics, such as tobramycin, for the treatment of Pseudomonas aeruginosa 
pulmonary infections are associated with the increase in life expectancy seen in cystic 
fibrosis (CF) patients over recent years. However, the effectiveness of this aminoglycoside is 
still limited by its inability to penetrate the thick DNA-rich mucus in the lungs of these 
patients, leading to low antibiotic exposure to resident bacteria. In this study, we created 
novel polymeric nanoparticle (NP) delivery vehicles for tobramycin. Using isothermal 
titration calorimetry, we showed that tobramycin binds with alginate polymer and, by 
exploiting this interaction, optimised the production of tobramycin alginate/chitosan NPs. It 
was established that NP antimicrobial activity against P. aeruginosa PA01 was equivalent to 
unencapsulated tobramycin (minimum inhibitory concentration 0.625 mg/L). Galleria 
mellonella was employed as an in vivo model for P. aeruginosa infection. Survival rates of 
90% were observed following injection of NPs, inferring low NP toxicity. After infection 
with P. aeruginosa, we showed that a lethal inoculum was effectively cleared by tobramycin 
NPs in a dose dependent manner. Crucially, a treatment with NPs prior to infection provided 
a longer window of antibiotic protection, doubling survival rates from 40% with free 
tobramycin to 80% with NP treatment. Tobramycin NPs were then functionalised with 
dornase alfa (recombinant human deoxyribonuclease I, DNase), demonstrating DNA 
degradation and improved NP penetration of CF sputum. Following incubation with CF 
sputum, tobramycin NPs both with and without DNase functionalisation, exhibited anti-
pseudomonal effects. Overall, this work demonstrates the production of effective 
antimicrobial NPs, which may have clinical utility as mucus-penetrating tobramycin delivery 
vehicles, combining two widely used CF therapeutics into a single NP formulation. This 
nano-antibiotic represents a strategy to overcome the mucus barrier, increase local drug 
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concentrations, avoid systemic adverse effects and improve outcomes for pulmonary 
infections in CF. 
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Introduction 
Chronic pulmonary infection with pathogenic bacteria, such as Pseudomonas aeruginosa, is a 
life-limiting factor in patients suffering from cystic fibrosis (CF) [1]. The CF lung is 
compromised by the build up of purulent viscous mucus secretions, which impairs 
mucociliary clearance and supports bacterial infection. This bacterial presence stimulates the 
release of neutrophil chemoattractants from epithelial cells and neutrophils, leading to further 
neutrophilia and increased viscosity of mucus; due to the release of DNA following 
neutrophil breakdown [2–4]. This exopolysaccharide and DNA-rich biopolymer network of 
mucus has significant impact on the success of antibiotic treatment in these patients. 
An important antibiotic used for CF lung infections caused by the Gram negative 
organism P. aeruginosa, is the aminoglycoside tobramycin [5–7]. Aerosolised delivery of 
tobramycin has been clinically adopted to alleviate the disadvantages of systemic 
administration, such as the narrow therapeutic index, low sputum concentrations and dose-
limiting nephrotoxicity and ototoxicity [8,9]. Recent development of tobramycin into a dry 
powder inhaler device Tobramycin Inhalation Powder™ (TIP), which has similar efficacy to 
the nebulised inhalation solution, has the advantages of improved convenience, portability 
and reduced treatment time burden [9–11]. However, the efficacy of tobramycin in CF 
patients is still limited by the ability to achieve sufficient levels at the site of infection. This 
can be attributed to rapid clearance of free drug, poor mucus and biofilm penetration and 
inactivation of the drug through binding interactions in these environments [12–14]. 
Therefore, novel strategies for improving tobramycin delivery could enhance the activity of 
this vital antibiotic.   
Key benefits of nanoparticle (NP) based antibiotic formulations for use in infectious 
diseases include prolonged retention at the target site and diminished systemic exposure 
leading to reduced risk of serious dose-related side effects associated with this drug class 
[12,15,16]. In this report, we outline the optimisation strategy and formulation considerations 
for tobramycin loaded alginate/chitosan NPs and demonstrate antimicrobial efficacy using in 
vitro and in vivo models of P. aeruginosa infection. Furthermore, to overcome the mucus 
barrier, we investigate a strategy for the utilisation of this nano-platform to deliver the 
antibiotic more effectively to the site of infection in the CF lung by conjugation of dornase 
alfa (recombinant human deoxyribonuclease I, DNase) to the tobramycin NPs. It was 
hypothesised that DNase, which reduces mucus viscoelasticity by cleavage of DNA [4], may 
improve antibacterial activity by enhancing drug penetration of the mucus network. 
Therefore, we undertook preliminary studies to explore the effects of DNase tobramycin NPs 
in CF sputum samples to determine DNase activity, mucus penetration and overall 
antimicrobial susceptibility. 
  
Methods 
Isothermal titration calorimetry 
A MicroCalorimeter iTC200 (GE Healthcare Life Sciences, UK) was used to investigate the 
interaction between sodium alginate (alginic acid sodium salt, Sigma-Aldrich, UK) and 
tobramycin by isothermal titration calorimetry (ITC) using a previously developed method 
[17]. Briefly, an initial injection (0.1 µL) of 9 mM tobramycin followed by 24 injections of 
0.3 µL tobramycin were titrated into the sample cell filled with 15 mM alginate with 3 minute 
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spacing between injections at a reference power 10 µCal/sec. The final figure and 
thermodynamic parameters were produced by subtracting the heats of dilution of tobramycin 
into water then fitted using the one set of sites model in the data analysis software MicroCal 
Origin
®
. The free energy of binding (ΔG) was calculated using the equation       
   , where ΔH is the enthalpy change, T is temperature (Kelvin) and ΔS is the change in 
entropy. 
 
Formulation and optimisation of tobramycin alginate/chitosan nanoparticles 
Solutions of sodium alginate (pH 5), tobramycin and chitosan (low molecular weight, Sigma-
Aldrich) (1% acetic acid, pH 4.8) were prepared in ultrapure water. Tobramycin was added to 
alginate (3 ml), stirred for 10 minutes then chitosan (1 ml) was added dropwise via a 25 G 
needle with pulsatory sonication over approximately 8 minutes. The NP suspension was 
stirred for 30 minutes, centrifuged at 16800 g, washed twice for a total of 45 minutes and the 
final NP pellet was re-suspended in 1 ml phosphate buffered saline (PBS). NP optimisation is 
outlined in Table 1. Volumes were kept constant for each formulation and weight ratios in mg 
of alginate:chitosan:tobramycin were varied. NP batches were prepared, observed aggregate 
formation recorded and if no aggregates formed, NP batches were characterised by Zetasizer 
(Zetasizer Nano ZS, Malvern Instruments Ltd, UK) measurements.  
Triplicate NP batches were diluted in PBS and measurements performed in duplicate, 
recording size (mean particle size Zave), polydispersity index (PDI) and zeta potential. 
Scanning electron microscopy was performed by drying small droplets (10 µL) of the final 
optimised formulation of tobramycin NPs on aluminium stubs, which were sputter-coated 
with gold and visualised (Jeol 6500 field emission gun, Japan). Stability studies were 
performed at 37°C with shaking at 120 rpm, measuring the size and PDI in PBS daily over 96 
hours. For the tobramycin release study, 2 ml of tobramycin NPs were injected via a 25 G 
needle into a Slide-A-Lyzer
®
 Dialysis Cassette 7000 MW (Thermo Scientific, UK) placed 
into 28 ml PBS reservoir, in a shaking incubator at 37°C. Samples of 200 µL were taken from 
the PBS reservoir at specified time points over 48 hours and tobramycin content was analysed 
compared to standards prepared in PBS. 
For tobramycin NPs, drug loading was calculated by analysis of tobramycin in the 
supernatants obtained during the wash steps. Calibration curves were prepared using known 
concentrations of tobramycin dissolved in the supernatant fluid obtained during washing of 
blank NPs. In this way, any interference was accounted for at each concentration. Based on a 
protocol of aminoglycoside detection [18] the product fluorescence was measured at 380/460 
nm (FLUOstar Optima, BMG Labtech) and the reagent consisted of 80 mg phthaldialdehyde 
dissolved in 1 ml ethanol, 0.2 ml diethyl ether, 0.2 ml boric acid 0.4 M pH 9.7 and 0.4 ml 2-
mercaptoethanol (all reagents Sigma-Aldrich). 
 
Antimicrobial activity  
Broth microdilution tests were performed to determine the minimum inhibitory concentration 
(MIC) of tobramycin against P. aeruginosa PA01. An overnight PA01 suspension in Luria-
Bertani (LB) broth was adjusted to optical density (OD) 0.3 (570 nm) and diluted 1:1000 to 
give approximately 5 x 10
5
 cfu/ml. This inoculum (100 µL) was added to 100 µL of 
tobramycin NPs and free tobramycin serially diluted two fold in LB broth from a starting 
concentration of 20 mg/L. Positive and negative growth controls and blank NPs at equivalent 
polymer concentrations were included. Following 18 hours incubation under shaking at 37°C, 
the absorbance at 570 nm was measured to determine the MIC as the lowest concentration at 
which no visible bacterial growth occurred (OD less than 0.15).  
Tobramycin NPs, free tobramycin (250 µg/ml) and PBS controls were tested alone for 
toxic effects in Galleria mellonella (livefoodsdirect.co.uk). P. aeruginosa (PA01) infections 
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were treated (i) 30 minutes following a lethal infection (NP 2.5, 25 and 250 µg/ml and free 
250 µg/ml tobramycin) (ii) pre-treatment (NP and free 250 µg/ml tobramycin) 96 hours prior 
to lethal infection. For each experiment, 10 larvae were injected with 20 µL into the last left 
pro-leg using a 29 G needle. A second injection was into the last right pro-leg. Uninfected 
controls were of two sterile PBS injections resulting in 90-100% survival in each experiment 
(data not shown). Percentage survival was plotted over 96 hours by recording the number of 
dead larvae during incubation at 37°C in the dark. Time zero, t=0, was the point of last 
injection during the toxicity screen or time of infection. Overnight PA01 cultures were grown 
in LB broth, centrifuged at 4000 g for 30 minutes, re-suspended in PBS to an OD 1.0 at 570 
nm and diluted to give a lethal dose after 24 hours (approximately 10
3
 cfu/ml).  
 
DNase tobramycin NPs 
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, Sigma-Aldrich) (3mg) was stirred 
with pre-formulated tobramycin NPs for 5 minutes then 0.5 ml DNase (1 mg/ml 
Pulmozyme®, Roche, UK) was added and stirred overnight. NPs were centrifuged for 30 
minutes at 16800 g and re-suspended in 1ml PBS.  
Rhodamine loaded DNase tobramycin NPs were formulated by adding 250 µL of 2 
mg/ml rhodamine 6G (Sigma-Aldrich) to the alginate solution. Rhodamine loaded no drug 
NPs (prepared without tobramycin and DNase) were used as controls. Rhodamine content 
was determined against a calibration curve prepared from rhodamine added to blank NPs 
(without rhodamine) immediately after formulation (time 0) and following 24 hours at room 
temperature to determine leaching of the dye from NPs. At each time point NPs were 
centrifuged for 30 minutes and washed in PBS. 
A standard protocol of bicinchoninic acid protein assay (BCA Protein Assay Kit, 
Thermo Scientific Pierce, UK) was followed to quantify DNase present in NPs against 
standards of known amounts of DNase added to blank NPs or rhodamine loaded no drug NPs 
as appropriate.  
 
NP evaluation in cystic fibrosis sputum  
Sputum from CF patients was obtained anonymously from the Adult CF centre at Belfast 
City Hospital. Sputum samples were in excess to requirements for diagnostic purposes. 
Permission to use sputum samples, which would have been disposed of, for validation 
purposes was given by the Director of R&D in Belfast Health and Social Care Trust. Sputum 
was frozen immediately at -80°C and used the next day after thawing at room temperature.  
For DNA degradation evaluation, 50 µg/ml DNase, free and conjugated to tobramycin 
NPs, blank NPs and PBS were incubated with CF sputum (ratio sputum:treatment 5:1) for 2 
hours at 37°C, then visualised by ethidium bromide staining and agarose gel electrophoresis. 
The penetration of rhodamine loaded DNase tobramycin NPs and rhodamine loaded 
no drug NPs through CF sputum was determined, based on a previously developed model 
[19]. A layer (0.25 ml) of 10% gelatin (Porcine type A, Sigma-Aldrich) was set in a 48 well 
microplate. To this, 0.25 ml sputum or PBS control was added and allowed to settle, then 0.1 
ml rhodamine loaded NPs were added. NPs were diluted to give DNase concentration of 50 
µg/ml and rhodamine loaded no drug NPs were diluted to provide equivalent rhodamine 
concentrations. After 24 hours at room temperature, the sputum/NP layer was removed, 
gelatin washed, melted and fluorescence measured at 480/520 nm. To calculate the 
percentage NPs penetrated through sputum, the fluorescence values of the gelatin in 
corresponding controls without a sputum layer were defined as 100% NP penetration. 
Duplicate measurements were carried out in three separate experiments. 
Treatment groups of DNase tobramycin NPs, tobramycin NPs, a mixture of 
tobramycin NPs plus free DNase, free tobramycin and PBS were tested against CF sputum 
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samples. Sputum samples were mixed thoroughly and a ratio of sputum:treatment 5:1 was 
incubated with shaking at 37°C for 24 hours. Samples were vortexed before serial tenfold 
dilutions in PBS were plated onto Pseudomonas isolation agar (Difco™, BD, UK) for viable 
counting. DNase tobramycin NPs were undiluted and other treatments made at equivalent 
drug concentrations. Results were normalised to the mean cfu/ml of the untreated PBS 
control, represented as percentage survival of P. aeruginosa. PBS controls ranged from 6 x 
10
6
 to 6 x 10
8
 cfu/ml. 
 
Statistical analysis  
Results were analysed with GraphPad Prism, version 5.03, GraphPad Software (San Diego, 
USA). G. mellonella survival shown as Kaplan-Meier plots and analysis was performed using 
the log rank (Mantel-Cox) test for significance. As detailed in figure legends, t-tests and one 
way ANOVA analyses were conducted. Statistical significance critical values were defined as 
*P < 0.05, **P < 0.01. 
 
Results 
Formulation and optimisation of tobramycin alginate/chitosan nanoparticles 
Given that tobramycin has a net positive charge, it was hypothesised that its properties were 
conducive to formulation into alginate-based NPs. Prior to NP formulation, this potential 
binding was studied through ITC. Tobramycin was injected into an alginate solution and, as 
shown in Figure 1, an exothermic reaction was observed, indicating binding between the two 
molecules. The values in the inset table calculated from Origin data analysis showed a 
dissociation affinity constant (KD) in the micromolar range (1.62 µM). The negative enthalpy 
change (ΔH = -40.33 kcal/mol) indicated a favourable reaction and the calculated entropy 
component (-TΔS) was positive and classified as unfavourable. However, the larger enthalpy 
compensated for this entropy and the free energy (ΔG) was also favourable, calculated to be -
7.98 kcal/mol. The negative free energy showed the process was enthalpically driven and 
indicated strong binding. 
 
Figure 1 
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Having confirmed the ability of tobramycin to interact with alginate, NP formulations using 
chitosan as a stabilising polymer were investigated whereby alginate and tobramycin were 
first mixed, followed by the addition of chitosan. This process has been referred to as 
nanoplex formation via self-assembly of polyelectrolytes [20]. Consistent with this previous 
work we observed the counterion (chitosan) is essential and a critical balance of the 
components was required for NP formation. Various parameters were investigated to arrive at 
an optimal formulation by altering the proportions of the three components (alginate, 
tobramycin and chitosan) as highlighted in Table 1.  
 
Table 1. Optimisation of the formulation of tobramycin alginate/chitosan nanoparticles.  
Formulation 
Component weight ratio (mg) 
alginate : chitosan : tobramycin 
Aggregates? 
Y, N
a
 
NP size range 
< 1000nm? 
N/A
b
, Y, N 
1 4 : 0.75 : 1.5 Y N/A 
2 4 : 1.5 : 1.5 Y N/A 
3 6 : 1.5 : 1.5 N Y 
4 6 : 3 : 1.5 Y N/A 
5 6 : 1.5 : 3 N N 
6 6 : 1.5 : 6 Y N/A 
7 9 : 1.5 : 1.5 N Y 
8 9 : 1.5 : 3 Y N/A 
a
Y, N: Yes or No. 
b
N/A: Not Applicable, size not measured due to aggregate formation. 
 
Two formulations chosen for further characterisation were 3 and 7 (Table 2). A low PDI of 
0.19 indicated the NP populations had a uniform size distribution and the zeta potentials were 
negative. Tobramycin content for formulation 3 was 91.7 µg/mg polymer whereas 
formulation 7 resulted in a lower drug loading of 41.1 µg/mg polymer. Therefore formulation 
3 was chosen for further work using the ratio of alginate:chitosan:tobramycin 6:1.5:1.5.  
 
Table 2. Tobramycin NP characterisation
a
. 
Tobramycin 
NP 
formulation 
Component weight ratio 
(mg) alginate : chitosan : 
tobramycin 
Size (nm) PDI 
Zeta 
potential 
(mV) 
Tobramycin 
content 
(µg/mg 
polymer
b
) 
Encapsulation 
efficiency
c
 
(%) 
3 6 : 1.5 : 1.5 
505 
± 32 
0.19 
± 0.06 
-25.7 
± 0.6 
91.7 
± 18.1 
45.8 
 ± 7.0 
7 9 : 1.5 : 1.5 
538 
± 43 
0.19 
± 0.03 
-28.0 
± 1.2 
41.1 
± 11.4 
20.6  
± 5.7 
a
n = 3 batches prepared on separate days, mean ± standard deviation.  
b
Polymer weight includes total of alginate and chitosan weights. 
c
(tobramycin amount in NP/tobramycin amount added initially)*100. 
 7 
 
The mean diameter measured by Zetasizer analysis of 505 nm was confirmed by scanning 
electron microscopy, highlighting spherical morphology of NPs (Figure 2 a). Under agitated 
conditions at 37°C, size and PDI of NPs were retained over 96 hours (Figure 2 b) and the 
tobramycin release study highlighted a typical biphasic release of the drug with 45% released 
in the first 90 minutes, which increased to 80% after 48 hours (Figure 2 c). This indicated that 
although the drug is able to interact with the alginate during formulation to achieve good 
encapsulation, it can still be successfully released. 
 
Figure 2 
 
Antimicrobial activity of tobramycin nanoparticles 
To examine the therapeutic effects of the nano-formulated tobramycin, the MIC was 
established against P. aeruginosa (PA01) (Figure 3). Tobramycin NPs demonstrated 
comparable antimicrobial effects to unencapsulated tobramycin: both MICs were 0.625 mg/L. 
This indicated that the potency of tobramycin had not been adversely affected by formulation 
processes. Again, despite the previously confirmed interaction with alginate, tobramycin was 
able to exert its antimicrobial effect. At equivalent NP polymer concentrations examined, 
blank NPs had no discernible effects on the visible growth of the bacteria.  
 
Figure 3 
 
The antimicrobial effects of the NPs were then evaluated in more detail towards PA01 
infection in vivo using a Galleria mellonella model. As a model for infection, it has strong 
 8 
evidence as an appropriate alternative method for studying novel antimicrobials with clinical 
relevance [21,22]. Firstly, the potential toxicity of tobramycin NPs was examined. No 
significant difference in survival was found between the NP-treated and untreated arms (90% 
survival, 96 hours, Figure 4 a). Next, the ability of the drug formulations to treat infection-
induced mortality was measured with bacteria (1.4 x10
3
 cfu/ml) administered at t=0 and drug 
treatment 30 minutes later. G. mellonella was sensitive to this low inoculum of PA01 as 
untreated larvae did not survive more than 24 hours, similar to previous responses with other 
P. aeruginosa strains [22,23]. Tobramycin prevented mortality in the larvae in a dose 
dependent manner. The NP dose of 2.5 µg/ml tobramycin did not enhance survival of 
infected G. mellonella, resulting in the same response as for the untreated group. With 
increasing doses of tobramycin, survival increased, where 25 µg/ml and 250 µg/ml showed 
40% and 90% survival respectively (Figure 4 b). These survival plots also showed that 
administration of free and NP formulated tobramycin (250 µg/ml) generated similar 
therapeutic benefit. It was hypothesised that the controlled release nature of the NPs could 
provide an extended therapeutic window. Therefore, a prophylactic study was prepared where 
the larvae were treated with either free or NP formulated tobramycin. PA01 bacteria were 
then introduced after an incubation period of 96 hours (t=0 post infection) and mortality was 
measured over a further 96 hours. The resulting effect was a significant enhancement of 
survival upon tobramycin NP treatment compared to the free drug, as shown in Figure 4 c. 
NPs offered a protective effect, providing 80% survival whereas the free drug showed only 
half this value at 40% survival after 96 hours.  
Figure 4 
 
DNase functionalisation of tobramycin nanoparticles 
DNase functionalisation was facilitated by the covalent crosslinking of DNase to tobramycin 
NPs using carbodiimide chemistry. These NPs were characterised as before (Table 3) 
producing negatively charged particles of a mean diameter 457 nm and polydispersity index 
0.21. Tobramycin loading was 69.6 µg/mg polymer, DNase content was 15.7 µg/mg polymer. 
Against PA01 cultures, DNase tobramycin NPs showed similar antimicrobial effects to the 
tobramycin NPs with a single point increase in MIC to 1.25 mg/L (supplementary figure 1).  
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Table 3. DNase tobramycin NP characterisation
a
. 
Size 
(nm) 
PDI 
Zeta 
potential 
(mV) 
Tobramycin 
content 
(µg/mg 
polymer
b
) 
Tobramycin 
encapsulation 
efficiency 
(%)
c
 
DNase 
content 
(µg/mg 
polymer
b
) 
MIC 
against 
PA01 
(mg/L) 
457 
± 12 
0.21 
± 0.01 
-23.0 
± 1.5 
69.6 
± 6.4 
34.8 
± 3.5 
15.7 
± 2.7 
1.25 
a
n = 3 batches prepared on separate days, mean ± standard deviation.  
b
Polymer weight includes total of alginate and chitosan weights. 
c
(tobramycin amount in NP/tobramycin amount added initially)*100. 
 
 
Supplementary figure 1 
 
It was hypothesised that functionalisation of tobramycin NPs with DNase, which reduces 
mucus viscoelasticity by DNA cleavage [4], may improve the antibacterial activity of 
tobramycin by enhancing drug penetration of the mucus network. As there was no suitable 
preclinical in vivo model available to reflect the viscous and infectious mucus environment in 
the CF lung, the efficacy of the NPs towards infected clinical CF sputum was examined 
instead. DNase activity was confirmed through its ability to degrade DNA found in CF 
sputum samples (Figure 5 a). DNA in CF sputum that was sham treated with PBS and blank 
NPs showed a characteristic smear of DNA. This was diminished after DNase treatment, 
indicating degradation of the high molecular weight DNA present. Crucially, the DNase 
functionalised NPs also degraded DNA, highlighting the ability of the formulation to break 
down DNA in clinical isolates. To ensure that NPs could penetrate the CF sputum and were 
not totally obstructed by the mesh network, a sputum penetration assay was employed. Using 
rhodamine 6G loaded NPs it was found that, following 24 hours incubation, the percentage of 
DNase tobramycin NPs transported across the sputum layer was significantly enhanced over 
the permeation of their dye loaded no drug NP equivalent (Figure 5 b). However it was also 
observed that these no drug NPs were not entirely obstructed and still had 30% penetration. 
Rhodamine loading of NPs was quantified at 0 and 24 hours and there was no detectable 
difference in the amount of rhodamine in NPs (supplementary figure 2), indicating any 
change in fluorescence was due to the presence of NPs in the gelatin layer, not leaching of the 
dye. 
 Finally, in a small group of sputum samples, we examined the antimicrobial efficacy 
of the tobramycin delivery vehicles. Untreated sputum samples had varying levels of P. 
aeruginosa ranging from 6 x 10
6
 to 6 x 10
8
 cfu/ml. All samples showed sensitivity to 
tobramycin as depicted in Figure 5 c, which also exemplifies the difference in responses 
between samples. For example, all tobramycin treatments of sample 4 resulted in very large 
bacterial kill, with less than 5% P. aeruginosa survival, whereas when sample 3 was treated 
with DNase tobramycin NPs there was 50% survival of bacteria. This was to be expected due 
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to the heterogeneous patient population.  Despite this, we found that in comparison to the 
other treatments, the DNase conjugated tobramycin NPs were equally effective and in two of 
four samples trended towards improved efficacy.  
Figure 5 
 
 
Supplementary figure 2 
 
Discussion 
Polymeric NP delivery of antibiotics has the potential to provide prolonged residence time at 
sites of infection, yield sustained therapeutic release and present site-specific targeting 
[12,15,24,25]. In this current work we developed an alginate-based NP system for 
tobramycin. This polymer has been shown to favour the encapsulation of hydrophilic drugs 
[17] and it was thought that the cationic nature of tobramycin would improve entrapment 
efficiency. Thermodynamic analysis of ITC data confirmed a strong interaction between 
alginate and tobramycin. The thermodynamic profile observed was similar to previous work 
with aminoglycosides [26] and alginate [27], where the favourable enthalpy suggested that 
hydrogen bonding and van der Waals interactions were the main forces dictating the 
interactions.  
Exploiting this tobramycin-alginate interaction, we successfully fabricated 
alginate/chitosan NPs with high drug loading, which is frequently a limitation of preparation 
of antibiotic NP formulations [20]. Alginate has been shown to improve tobramycin 
encapsulation [19] and, in comparison to these poly(lactide-co-glycolide) acid (PLGA) NPs, 
the formulation developed here requires minimal organic solvent use. In addition to no 
requirements of extreme conditions during formulation, our NP production lends itself to 
economic and environmental efficiency. The pH (4.8-5) and mixing order of the NP 
components determines the mechanism of formation of the NPs. The first step was to mix the 
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large polysaccharide alginate with the oppositely charged molecule tobramycin and, as 
verified by ITC, interactions occurred allowing for ionic crosslinking. Upon addition of the 
large polyelectrolyte chitosan, the crosslinking was reinforced by further electrostatic 
interactions forming a polyelectrolyte complex [28]. The formation of NPs via the 
polyelectrolyte complexation of negatively charged alginate with positively charged chitosan 
has been exploited for a variety of drugs whose optimal formulation ratio of components 
proved similar to our studies [17,29–31]. In agreement with other studies [20,32,33] drug 
loading did not simply correlate with increasing polymer content during NP formulation, 
highlighting the need for empirical determination and optimisation.  
The efficacy of the high-drug loaded tobramycin NPs was evaluated using the G. 
mellonella infection model. This model has been shown to have positive correlation with 
mammalian models in determining virulence against P. aeruginosa [23] and its use as an 
infection model has many advantages over conventional mammalian models, such as low 
cost, ease of experimentation and ethical acceptability [34]. Antibiotic susceptibilities, 
pharmacokinetic and pharmacodynamic properties have been successfully determined in G. 
mellonella and it proves to be valuable in assessing antimicrobials [21,22,35]. The use of an 
invertebrate model with a functioning immune system provides further insight and allows 
refinement of the efficacy of novel antimicrobial delivery systems at this early stage in the 
drug development process. We have shown here that tobramycin NPs were able to rescue 
larvae from a lethal infection of PA01. The comparable antimicrobial efficacy of NPs and 
free tobramycin reflected the similar MIC values. This is in agreement with the previously 
shown correlation between in vitro and in vivo sensitivities [22]. Crucially, NP pre-treatment 
results in this systemic model proved superior to free tobramycin. This suggests that the NP 
delivery system acts as an antibiotic depot providing sustained antibiotic concentrations 
above the MIC, which is desirable for improving therapeutic outcomes in infections. The 
normal pharmacokinetic clearance mechanisms of free drugs in vivo may have been 
overcome by NPs, highlighting a major advantage of NP therapy, as we have observed 
previously [25].  
An important parameter for targeting infections residing in the lungs of CF patients is 
effective penetration of the barrier posed by lung mucus. Viscoelastic CF mucus contains 
raised levels of DNA and actin from neutrophils, pathogens and epithelial cells [2]. These 
components, combined with the ability of bacteria to grow in biofilms, create a potent barrier 
to treatment of colonised lungs [14,36–38]. In this report, we have focused on DNA as a 
barrier in CF sputum. Clinically, DNase (Pulmozyme) is inhaled to improve lung function 
and clearance and to reduce the viscosity of the mucus in CF lungs [3,4,39]. By 
functionalising DNase to NPs, we showed cleavage of DNA in CF sputum and demonstrated 
this enhanced NP penetration, providing evidence for a barrier effect of DNA. Previously the 
use of adjuvant DNase treatments with NPs has been assessed [37,40,41] but the work here 
represents the first attempt to functionalise NPs with active DNase.   
Antimicrobial efficacy of DNase tobramycin NPs was shown against P. aeruginosa, 
with slight variation in the MIC compared to tobramycin NPs, similar to previous work [19]. 
In our initial evaluation of antimicrobial activity in CF sputum samples, we found 
heterogeneity in the bacterial load and this may have impaired the ability to produce 
significantly enhanced therapeutic effects with the DNase functionalised NPs. Nonetheless, 
the results show that NPs are at least as efficacious as unencapsulated tobramycin and in 
future studies with larger cohorts of matched patient samples these effects may be more 
apparent.  
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The development of mucus penetrating drug carriers which offer sustained levels of 
therapeutics at mucosal surfaces has great potential. In this investigation we have shown the 
optimisation strategy of an alginate/chitosan nanoparticle drug delivery system for 
tobramycin. We demonstrated the efficacy of tobramycin NPs against P. aeruginosa 
infections both in vitro and in vivo in the Galleria mellonella model. We further showed the 
versatility of tobramycin NPs by designing dual modality NPs incorporating DNase, which 
showed effective penetration and anti-pseudomonal activity in CF patient sputum. The results 
presented here further support the utility of nano-antibiotic technology and in agreement with 
recent literature [12], our tobramycin polymeric NPs have high antibiotic loading, stability 
and mucus penetration abilities, which are the unmet desirable properties for such a delivery 
system for CF pulmonary infection therapies. Successful delivery of antimicrobials to 
difficult-to-penetrate sites of chronic infection is essential to improve therapeutic outcomes in 
CF lung infections and it is hoped future drug design would consider barriers to drug 
delivery, efficacy and patient adherence. Our polymeric nano-antibiotics represent a 
promising strategy in the battle to treat pulmonary infection in the hostile environment of the 
CF lungs.  
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Figure Legends 
Figure 1. Isothermal titration calorimetry: titration of tobramycin (9 mM) into alginate (15 
mM). The inset table shows calculated thermodynamic parameters by Origin analysis and the 
equation ΔG = ΔH – TΔS. Figure is representative of three experiments, inset table data n=3, 
mean ± standard deviation. 
Figure 2. Tobramycin NP Characteristics. (a) Scanning electron microscope image of 
tobramycin NPs (b) NP size and PDI measurements over 96 hours from time of formulation 
(0 h). 3 NP batches, mean ± SEM (c) Tobramycin NP release profile in PBS at 37°C over 48 
hours. n=2, mean ± SEM.  
Figure 3. MIC determination against P. aeruginosa PA01: free tobramycin, tobramycin NPs 
and blank NPs. Blank NP points representative of the equivalent polymer concentration of the 
tobramycin NPs at the specific tobramycin concentration tested. MICs of both free and NP 
tobramycin were 0.625 mg/L. n=3, mean ± SEM. 
Figure 4. Galleria mellonella PA01 infection model. (a) PBS, free tobramycin and 
tobramycin NPs, followed by an injection of PBS (no infection) to determine NP toxicity. (b) 
Tobramycin treatment following lethal PA01 infection. (c) Pre-treatment protocol: PA01 
infection introduced after 96 h incubation. n=10 G. mellonella per group, percentage survival 
monitored over 96 h. Log rank (Mantel-Cox) test for significance **P < 0.01. 
Figure 5. Bioactivity of DNase tobramycin NPs in CF Sputum. (a) Gel electrophoresis image 
of CF sputum incubated with PBS, blank NP, free DNase and DNase tobramycin NP. Image 
representative of 3 sputum samples. (b) Ability of rhodamine loaded no drug NPs and 
rhodamine loaded DNase tobramycin NPs to penetrate CF sputum. Data presented as % NPs 
penetrated compared to a no sputum (PBS layer) control, n=3, mean ± SEM. Unpaired t-test 
*P < 0.05 (c) Treatment of CF sputum with PBS, free tobramycin, tobramycin NP, 
tobramycin NP and free DNase, DNase tobramycin NP.  Undiluted sputum samples (3-6 
replicates per sample) treated for 24 h. Data normalised to PBS control (100% survival), 
represented as percentage survival of P. aeruginosa ((cfu ml
-1
 treatment / mean cfu ml
-1 
PBS) 
*100) for 4 independent samples.  
Supplementary figure 1. MIC determination against P. aeruginosa PA01: DNase 
tobramycin NPs. MIC was 1.25 mg/L. n=3, mean ± SEM. 
Supplementary figure 2. Release of rhodamine from no drug and DNase tobramycin NPs 
loaded with rhodamine 6G, at room temperature over 24 h. n=2, mean ± SEM. 
 
